24/7 Market News Snapshot 16 June, 2025 – Sage Therapeutics, Inc (NASDAQ:SAGE)

June 16, 2025

DENVER, Colo., 16 June, 2025 (www.247marketnews.com) – (NASDAQ:SAGE) are discussed in this article.
Sage Therapeutics, Inc. has agreed to a strategic acquisition by Supernus Pharmaceuticals, Inc. in a cash tender offer valued at approximately $795 million. This move comes as Sage’s stock experiences a significant surge, rising 35.67% in pre-market trading, reflecting strong investor confidence as it climbs to a price of $9.09. The deal is anticipated to close in the third quarter of 2025, signaling a robust expansion of Supernus’s portfolio, especially in the treatment of neuropsychiatric conditions.

At the heart of this acquisition is ZURZUVAE® (zuranolone), which has gained recognition as the first FDA-approved oral medication for adults dealing with postpartum depression. Supernus aims to utilize its established market presence and distribution infrastructure to accelerate the growth and commercialization of ZURZUVAE, capitalizing on its innovative approach to addressing mental health issues.

The financial structure of the acquisition involves an upfront payment of $8.50 per share, alongside a contingent value right (CVR) that could yield an additional $3.50 per share, based on specific sales milestones. This brings the overall deal valuation to approximately $12.00 per share, reinforcing Supernus’ commitment to enhancing its product offerings, which already include a selection of high-growth products.

Jack Khattar, President and CEO of Supernus, highlighted that this acquisition marks a critical juncture for the company, aimed at diversifying its revenue streams and bolstering its growth trajectory. Sage’s CEO, Barry Greene, echoed this sentiment, viewing the transaction as a testament to the company’s dedication to innovation in brain health. With expectations of significant revenue and cash flow enhancements, combined with projected annual cost synergies of around $200 million, the acquisition is set to reshape the competitive landscape in the pharmaceutical sector.

Related news for (SAGE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.